Coexisting depressive symptoms do not limit the benefits of chronic neuromodulation: A study of over 200 patients

Aims To examine the relationship between coexisting depressive symptoms and outcomes after staged neuromodulation procedures for refractory urological symptoms. Methods Adults who enrolled in a prospective database and completed a Personal Health Questionnaire Depression Scale (PHQ‐8) at baseline were reviewed. The PHQ‐8 and Generalized Anxiety Disorder (GAD‐7) assessed depressive/anxiety symptoms pre and 6 months post device implant. Urological symptoms were assessed with The Interstitial Cystitis Symptom Index/Problem Index (ICSI‐PI) and Overactive Bladder Questionnaire (OAB‐q) at baseline, 3 and 6 months, and Global Response Assessments (GRA) post implant. Subjects, grouped by PHQ